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Markers of angiogenesis and macrophage products
for predicting disease course and monitoring
vascular inflammation in giant cell arteritis
Yannick van Sleen1, Maria Sandovici1, Wayel H. Abdulahad1, Johan Bijzet1,
Kornelis S. M. van der Geest 1, Annemieke M. H. Boots1 and
Elisabeth Brouwer1
Abstract
Objective. GCA, a systemic vasculitis, is characterized by an IL-6-dependent acute-phase response. This response is
typically suppressed by treatment rendering CRP/ESR unreliable for monitoring vascular inflammation. Also, there are no
accurate biomarkers predicting a non-favourable disease course. Here we investigated macrophage products and
markers of angiogenesis as biomarkers for prognosis and monitoring of vascular inflammation.
Methods. Forty-one newly diagnosed, glucocorticoid-naive GCA patients were prospectively followed for relapses and
glucocorticoid requirement for a median of 30 months (range 071). Serum markers at baseline and during follow-up were
compared with 33 age-matched healthy controls and 13 infection controls. Concentrations of IL-6, serum amyloid A,
soluble CD163, calprotectin, YKL-40, VEGF, angiopoietin-1 and -2 and sTie2 were determined by ELISA/Luminex assay.
Results. Serum concentrations of all markers, but not angiopoietin-1, were elevated in GCA patients at baseline when
compared with healthy controls. High VEGF (P= 0.0025) and angiopoietin-1 (P= 0.0174) and low YKL-40 (P= 0.0369)
levels at baseline were predictive of a short time to glucocorticoid-free remission. Elevated angiopoietin-2 levels were
associated with an imminent relapse during treatment (P< 0.05). IL-6 correlated strongly with acute-phase markers and
soluble CD163 but not with markers of angiogenesis, YKL-40 or calprotectin. Glucocorticoid treatment down-modulated
all markers except for calprotectin and YKL-40. Tissue expression of markers in temporal arteries was confirmed.
Conclusion. Markers of angiogenesis at baseline and during treatment predict GCA disease course, suggesting utility
in patient stratification for glucocorticoid-sparing therapy. Calprotectin and YKL-40 are candidate markers for monitoring
vessel wall inflammation.
Key words: angiogenesis, angiopoietin-2, biomarkers, calprotectin, giant cell arteritis, glucocorticoids, IL-6,
macrophages, VEGF, YKL-40
Rheumatology key messages
. A serum profile of angiogenesis predicts disease course in giant cell arteritis patients.
. CRP and ESR do not predict disease course and lose value during glucocorticoid treatment.
. Calprotectin and YKL-40 qualify as candidate markers for monitoring vascular inflammation.
Introduction
GCA is the most common inflammatory disease of
medium and large arteries [1]. Involvement of cranial
arteries in GCA (C-GCA) can lead to symptoms like
headache, jaw claudication and vision loss [2]. Signs
and symptoms of inflammation of the aorta and its
branches [large vessel GCA (LV-GCA)] are less specific
and include weight loss and low-grade fever. Ultimately,
LV-GCA can lead to the formation of aneurysms and
aortic dissection [3, 4].
The most common treatment for GCA remains high-
dose and long-term glucocorticoid (GC) monotherapy.
However, many patients relapse, and the burden of GC
treatment adds to that of the disease itself, with a great
impact on patients’ quality of life [57]. Still, a subset of
patients experience a more favourable, non-relapsing
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disease course requiring short-term GC treatment.
To prevent GC toxicity and the risk of relapse, there is
an urgent need for biomarkers that, either at baseline
or during treatment, can predict disease course in
GCA. Recently IL-6 receptor (IL-6R) blocking therapy
(tocilizumab) has become available as GC-sparing treat-
ment [8].
Classically, IL-6-dependent acute-phase markers CRP
and ESR are used in the diagnosis and monitoring of GCA
[6, 7]. However, in 516% of newly diagnosed GCA pa-
tients, CRP and ESR levels are within the normal range
[9, 10]. In addition, although both GC and tocilizumab
treatment strongly suppress the synthesis of these mar-
kers [7, 8], disease activity may persist [7, 11, 12]. In line
with this notion, recent studies have shown ongoing
vessel inflammation, despite normalization of CRP and
ESR, under GC treatment [13] as well as under tocilizu-
mab treatment [11, 12]. Recent meta-analyses on serum
markers in GCA concluded that there are no reliable sero-
logical markers for monitoring or prognosis [14, 15]. Thus
there is an unmet need for IL-6-independent biomarkers
that accurately reflect disease activity and vessel wall in-
flammation during treatment with GCs or tocilizumab.
In an effort to identify prognostic biomarkers and bio-
markers for monitoring disease activity, we took clues
from GCA characteristic pathogenic processes at the
tissue level; these include vessel wall granulomatous infil-
trates and neoangiogenesis [1618]. Consequently, we
hypothesized a role for macrophage products and mar-
kers of angiogenesis as novel candidate biomarkers.
Monocytes and macrophages are capable producers of
IL-6 [19], a cytokine known to stimulate hepatocytes to
produce acute-phase response markers, including
serum amyloid A (SAA) [20, 21]. During inflammation,
monocytes/macrophages also release calprotectin,
sCD163 and YKL-40 [2224]. Inflamed GCA vessels are
characterized by new vessel formation involving VEGF,
angiopoietin-1 and -2 and sTie2 as key regulators in this
process [2527].
We thus compared the performance of these nine sol-
uble markers at baseline with those of CRP and ESR using
serum samples prospectively collected over 7 years in our
GCA cohort. We established their association with the
IL-6-driven acute-phase response. Next we investigated
these markers for prediction of disease course and ana-
lysed the effects of GC treatment on these markers to




Forty-one newly diagnosed, treatment-naive GCA pa-
tients participated in the study (Table 1). Patients were
diagnosed based on clinical signs and symptoms in com-
bination with either a positive temporal artery biopsy (TAB)
and/or a positive 18F-fluorodeoxyglucose PET-CT scan.
In this study, 27 of 41 GCA patients fulfilled the 1990
ACR criteria. The ACR criteria are useful in the diagnosis
of C-GCA rather than LV-GCA. Blood samples were ob-
tained before noon and all donors were non-fasted. Thirty-
three age- and sex-matched healthy controls (HCs) and
13 age-matched infection controls (INFs) were included as
well. HCs were screened for past and present morbidities.
Hospitalized INFs were included only if diagnosed with
pneumonia or a urinary tract infection. They were
excluded in case of comorbid diseases such as cancer
or diabetes and/or treatment with immunosuppressive
drugs. Written informed consent was obtained from all
study participants. All procedures were in compliance
with the Declaration of Helsinki. The study was approved
by the institutional review board of the University Medical
Center Groningen (METc2010/222 for GCA and INFs and
METc2012/375 for HCs).
Follow-up
GCA patients were prospectively followed, during which
time they visited the outpatient clinic according to a fixed
study protocol. In case of reappearance of clinical signs
and symptoms, a relapse visit was planned. Remission or
relapse was defined based on clinical signs and symp-
toms of GCA. CRP or ESR levels were not taken into
TABLE 1 Baseline characteristics of GCA patients and controls
Characteristics HCs GCA INFs
n 33 41 13
Age, years, median (range) 67 (5083) 71 (5289) 74 (4797)
Female, n (%) 22 (67) 28 (68) 4 (31)a
GCA diagnosis (TAB/PET-CT/both), n NA 13/19/9 NA
GCA symptoms (cranial/systemic/combined), n NA 11/8/22 NA
Fulfilled ACR criteria, n (%) NA 27 (66) NA
PMR clinic, n (%) NA 10 (24) NA
Ischaemic ocular involvement, n (%) NA 11 (27) NA
Claudication, n (%) NA 22 (54) NA
Follow-up, months, median (range) NA 30 (071) NA
aThe three groups did not significantly differ in age, but significantly fewer IFNs were female compared with the other groups
(2 test, P< 0.05). NA: not applicable.
2 https://academic.oup.com/rheumatology
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account, in line with the analysis of the GiACTA trial [8]. At
3 months (range 4 weeks; n= 30), 6 or 9 months (S.D.
10 weeks; n= 5) and 12 months (S.D. 10 weeks; n= 29),
follow-up samples were collected as per protocol
(Supplementary Fig. S1 and Table S1, available at
Rheumatology online).
To investigate differences in biomarker levels in remis-
sion patients who would or would not relapse within a time
frame of 4 months, samples were identified, grouped and
compared (Supplementary Fig. S1 and Table S1, available
at Rheumatology online).
Treatment
All patients were treated with GCs, which were tapered in
agreement with the British Society for Rheumatology
guidelines [28]; in short, a starting dose of 4060 mg/day
and tapering by 10 mg every 23 weeks to 20 mg/day, fol-
lowed by more gradual tapering. Tapering was done when
clinical signs and symptoms of disease activity were
absent, preferably with normalization of CRP and ESR.
In case of a relapse, the GC dose was increased and/or
a conventional synthetic DMARD was added (MTX or
LEF). GC-free remission was defined as an absence of
signs and symptoms, no GC use and no return of active
disease within at least 6 months of follow-up. Treatment-
free remission was defined as no signs and symptoms, no
GCs or other DMARDs and no return of active disease for
a period of at least 6 months of follow-up. Serum marker
levels were assessed in samples of eight patients having
achieved treatment-free remission.
Laboratory measurements
Serum marker levels were determined by ELISA or Luminex.
Immunohistochemistry was performed on five GCA-positive
TABs. A more detailed description of the methods can be
found in the supplementary material, section Supplementary
Methods, available at Rheumatology online.
Statistical analysis
Non-parametric tests (two-tailed) were used to analyse
the data (differences between groups). Comparisons be-
tween baseline patients and control groups were done by
KruskalWallis and MannWhitney U tests. Also, the
MannWhitney U test was used for comparison of
follow-up samples with HCs, comparison of samples
from active patients and patients in remission during treat-
ment and comparison of remission patients who would or
would not relapse within 4 months. Paired testing was per-
formed to compare follow-up samples and baseline sam-
ples using the Wilcoxon signed rank test. Correlations
between biomarkers were assessed using Spearman’s
rank correlation coefficient. To compare the time to GC-
free remission of patients with high levels of serum mar-
kers at baseline to patients with low levels, the log rank
test was used. The log rank test was used as well to cal-
culate hazard ratios for long-term GC requirement.
Analyses were performed with SPSS 23 (IBM, Armonk,
NY, USA) and GraphPad Prism 7.0 (GraphPad Software,
San Diego, CA, USA) software.
Results
Follow-up patient characteristics
The median follow-up duration of GCA patients was
30 months (range 071). Of 41 patients in the cohort, 15
reached GC-free remission in a median of 21 months
(range 847) (Supplementary Table S1, available at
Rheumatology online).
Elevated levels of inflammatory and angiogenesis
serum markers in newly diagnosed GCA patients
Macrophage products (calprotectin, YKL-40, sCD163)
and markers of angiogenesis (VEGF, angiopoietin-2,
sTie2) were significantly higher in newly diagnosed, GC
treatment-naive GCA patients (n= 41) compared with
age- and sex-matched HCs (n= 33) (Fig. 1,
Supplementary Fig. S2 and Table S2, available at
Rheumatology online). In contrast, angiopoietin-1 levels
were not elevated. As expected, ESR and acute-phase
markers (CRP, IL-6 and SAA) were also elevated. Most
markers were also found to be elevated in INFs (n= 13),
indicating that these markers are not disease specific.
Interestingly, ESR and angiopoietin-2 levels were clearly
elevated in four of five patients with low CRP levels, sug-
gesting that these markers could add to diagnosis
(Supplementary Table S3, available at Rheumatology
online).
Acute-phase response and GCA clinic
Patients with combined cranial and systemic symptoms
had a significantly higher acute-phase response com-
pared with patients with isolated cranial or systemic
symptoms (Table 1, supplementary material, section
Supplementary Methods, available at Rheumatology
online). CRP and ESR were significantly higher in the com-
bined group (n= 22) when compared with the isolated cra-
nial group (n= 11, P< 0.05) or the isolated systemic group
(n= 8, P< 0.05). IL-6, SAA and sCD163 were also signifi-
cantly higher in the combined group compared with the
isolated cranial group (P< 0.05). No differences were
found for the other macrophage and angiogenesis
markers.
Levels of acute-phase markers were lower in patients
with ischaemic ocular involvement (n= 11, P< 0.05 for IL-
6 and SAA). Interestingly, this was not typical for patients
with other ischaemic symptoms in both C- and LV-GCA
(e.g. jaw claudication and limb claudication; n= 22). No
differences were found for the other markers.
Baseline inflammatory and angiogenesis serum
marker correlations
Next we investigated serum marker correlations. As ex-
pected, levels of CRP, ESR and SAA were strongly corre-
lated with IL-6 in newly diagnosed GCA patients (n= 41;
Fig. 2A). Also, we found a strong correlation of sCD163
with IL-6 and the acute-phase markers. In contrast, YKL-
40 correlated only weakly with IL-6 and SAA. No correl-
ations were found for IL-6 and macrophage marker
https://academic.oup.com/rheumatology 3
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calprotectin. No or weak correlations were seen for mar-
kers of angiogenesis with IL-6 or the acute-phase
response.
Interestingly, in INFs, IL-6 correlated strongly with cal-
protectin, YKL-40 and angiopoietin-2, whereas correl-
ations of IL-6 with SAA and sCD163 were absent (n= 13;
Fig. 2B).
Expression of macrophage and angiogenesis markers
in TABs at diagnosis
To confirm that markers of macrophages are expressed at
the site of GCA pathology, consecutive TAB sections
(n= 5) were stained for calprotectin and YKL-40 by immu-
nohistochemistry (IHC; Fig. 3). To identify macrophage-
rich areas, sections were stained with CD68 and CD163.
In addition, we stained for VEGF and angiopoietin-2 as
markers of angiogenesis. Newly formed vessels were
identified by staining of CD34+ endothelial cells.
Expression of IL-6 and SAA was assessed as markers of
the acute-phase response. We did not investigate the ex-
pression of angiopoietin-1, as serum levels were not
modulated in GCA, nor sTie-2, as there are no IHC re-
agents available.
All markers were found to be expressed in the tissue.
Massive staining was observed for YKL-40 and angiopoie-
tin-2. As expected, expression of all markers was found
mostly in macrophage-rich areas, but endothelial cells
also appeared to express IL-6, VEGF and angiopoietin-
2. As calprotectin may also be expressed by neutrophils,
we checked their presence by CD15 staining. Few CD15+
cells were found (data not shown).
Angiogenic markers at baseline predict time to GC-
free remission
Next we determined if baseline serum marker levels could
predict disease outcome. To that end we compared the
time to GC-free remission in patients with serum levels
below the median (low) and above the median (high).
High relative levels of VEGF and angiopoietin-1 and low
relative levels of YKL-40 at baseline were found to predict
a short time to GC-free remission (Fig. 4). In addition, a
strong trend was seen for low levels of angiopoietin-2,
predicting a short time to GC-free remission. The hazard
ratio for long-term GC requirement per biomarker was
calculated: 5.5 for lower than median VEGF (95% CI 2.0,
15.3), 3.5 for lower angiopoietin-1 (95% CI 1.3, 9.8), 2.8 for
higher YKL-40 (95% CI 1.0, 8.2) and 2.9 for higher angio-
poietin-2 (95% CI 1.1, 8.0).
Calprotectin and YKL-40 remain elevated during GC
treatment
To identify markers associated with ongoing vascular in-
flammation in spite of GC treatment, we investigated the
effects of GC treatment on all candidate markers. After 3
and 12 months (n= 30 and n= 29, respectively; Fig. 5A, B)
of GC treatment, levels of most markers were found to be
decreased compared with baseline, even though many
remained significantly elevated compared with HCs.
FIG. 1 Serum marker levels in newly diagnosed GCA patients compared with INFs and HCs
Serum levels of calprotectin, YKL-40, sCD163, VEGF, angiopoietin-2 and sTie2 in newly diagnosed GCA patients
compared with IFNs and HCs. All markers were significantly higher in newly diagnosed, treatment-naive GCA (n= 41) and
in INFs (n= 13) as compared with age-matched HCs (n= 33). Since the KruskalWallis test showed a significant difference
between groups (P< 0.05), differences between individual groups were tested with the MannWhitney U test. The
horizontal line represents the median. Statistical significance is indicated by P-values in the graphs.
4 https://academic.oup.com/rheumatology
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Importantly, calprotectin and YKL-40 levels remained
mostly unaffected by GCs and could thus reflect asymp-
tomatic smouldering vessel wall inflammation.
Angiopoietin-1 levels were significantly higher in active
patients compared with patients in remission at 12 months
(P< 0.05; Fig. 5B). YKL-40 correlated with the treatment-
reduced ESR, CRP and IL-6, suggesting that YKL-40 may
identify ongoing subclinical inflammation in spite of treat-
ment (Supplementary Fig. S3, available at Rheumatology
online).
Angiopoetin-2 elevated in remission patients with an
imminent relapse
Next we assessed marker levels associated with future
relapses in remission patients (all within 12 months of
GC treatment; see Supplementary Fig. S1 and Table S1,
available at Rheumatology online). To this end we com-
pared remission patients that would relapse within a
period of 4 months (n= 14, future relapse) with those that
would not relapse in 4 months (n= 35). Angiopoietin-2
levels were significantly higher in the future-relapsing
group (Fig. 5C). The data are in line with increased
hazard ratio’s for long-term GC requirement associated
with high angiopoietin-2 levels (see above, Fig. 4).
Extended elevation of markers in treatment-free
remission
There is a paucity of data on serum markers in treatment-
free remission, as these samples are rarely available. To
answer the question of whether treatment leads to nor-
malization of serum markers in treatment-free remission,
we assessed serum marker levels in a small group of pa-
tients (n= 8; Supplementary Fig. S1, available at
Rheumatology online). Levels of IL-6, ESR, sCD163,
angiopoietin-1 and -2 and calprotectin remained signifi-
cantly elevated compared with HC levels (Fig. 5D).
Calprotectin levels were persistently high throughout the
whole disease course, while angiopoietin-1 levels
FIG. 2 Baseline inflammatory and angiogenesis serum marker correlations
Depicted are Spearman’s correlation coefficients for all markers in (A) newly diagnosed, treatment-naive GCA patients
and (B) INFs. The strength of correlation is indicated by cell colours. Statistical significance is *P< 0.05 or **P< 0.01.
https://academic.oup.com/rheumatology 5
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FIG. 3 Representative IHC stainings of consecutive sections in a positive TAB of a treatment-naive GCA patient
Paraffin-embedded tissues were stained with antibodies against (A) calprotectin, (B) YKL-40, (C) CD68, (D) CD163, (E)
VEGF, (F) angiopoietin-2, (G) CD34, (H) IL-6 and (I) SAA. Regions of interest (red) are magnified and are shown in the
lower right corner.
FIG. 4 Angiogenesis markers and YKL-40 at baseline predicted short-term GC treatment in GCA
Baseline serum marker levels were split in GCA patients by low and high levels (based on the median) and were plotted in
a KaplanMeier curve against time to GC-free remission. Strong trends and significant differences of the log rank test are
indicated as P-values in the graphs. Like CRP and IL-6, baseline levels of ESR, SAA, sCD163, calprotectin and sTie2
were not predictive of time to GC-free remission (data not shown).
6 https://academic.oup.com/rheumatology
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increased only after at least 12 months of treatment
(Fig. 5E). Interestingly, YKL-40 levels remained elevated
during 12 months of treatment but eventually normalized
in treatment-free remission. Fluctuations of the other mar-
kers over time are shown in Supplementary Fig. S4, avail-
able at Rheumatology online.
Discussion
GCA remains difficult to treat, as the current treatment
strategy with GCs is a trade-off between their variable
efficacy and their side effects. The goal of treatment in
GCA is to reach stable GC-free remission as quickly as
possible. Currently only scarce evidence suggests that
serum markers may predict disease course in GCA [14].
In this study, we found that serum markers of
angiogenesis at baseline predicted not only time to GC-
free remission (VEGF, angiopoietin-1 and YKL-40), but
were also associated with an imminent relapse while on
treatment (angiopoietin-2). Thus these markers may aid
the stratification of patients eligible for a quick or slow
GC tapering scheme. In addition, we identified macro-
phage products as markers of vessel wall inflammation
that may be used for monitoring vascular disease during
and after treatment.
We found several markers of angiogenesis (VEGF,
angiopoietin-2 and sTie2) to be upregulated in GCA.
Neoangiogenesis is instigated by disruption of homeo-
static angiopoietin-1Tie2 signalling by angiopoietin-2
(competing for binding the Tie-2 receptor) and sTie2 (as
decoy receptor) in the presence of VEGF [26, 27]. In GCA
TABs, we indeed found VEGF and angiopoietin-2
FIG. 5 Changes in serum biomarker concentrations during and after treatment
Radar plots showing biomarker levels expressed as fold changes compared with GCA baseline values. (A) Patients in
remission (n= 24) or active disease (n= 6) at 3 months after the start of treatment. (B) Patients in remission (n= 20) or
https://academic.oup.com/rheumatology 7
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expressed in neoangiogenic areas, likely triggered by hyp-
oxia [29]. Our findings highlight the importance of new
vessel formation at the site of inflammation in GCA to
fuel the ongoing inflammatory process and are in line
with previous studies reporting on elevated levels of
VEGF in GCA. However, these studies did not investigate
this marker in longitudinal follow-up studies [25, 30, 31].
We found that high levels of serum VEGF and angio-
poietin-1 at baseline were predictive of a short time to GC-
free remission. In contrast, high levels of angiopoietin-2,
tended to be predictive of a non-favourable disease
course. Moreover, elevation of angiopoietin-2 preceded
relapses during treatment. Thus markers of angiogenesis
impact the disease course in GCA. The protective effect of
VEGF may be explained by its potential to repress CD4+ T
cell proliferation and activation. CD4+ T cells, key players
in GCA pathogenesis, express VEGFR2, but not the
angiopoietin receptor Tie2 [32]. However, the notion of
protective features of VEGF was not substantiated in an-
other study in which VEGF was reported to amplify T cell
pathogenic effector functions in GCA [33].
Worldwide, CRP is increasingly being used for GCA
diagnosis instead of ESR, however, diagnosis is typically
difficult in patients with low CRP [9, 10]. We propose that
elevated angiopoietin-2 may have utility in diagnosis of a
small subset of GCA patients with low CRP. Angiopoietin-
1 levels were not altered at baseline and during treatment.
In treatment-free remission patients, however, increased
levels of angiopoietin-1 were found, which may suggest a
role in microvessel stabilization. So far, serum levels of
angiopoietins and their decoy receptor sTie2 [27] have
not been documented in GCA. Clearly, more fundamental
studies are needed to elucidate the role of angiopoietins in
GCA.
In this study we provide evidence for the notion of IL-6-
independent biomarkers of vessel inflammation at base-
line and during treatment. The monocyte/macrophage
products calprotectin and, to a lesser extent, YKL-40
are IL-6-independent. Moreover, both markers remain ele-
vated in spite of treatment and thus qualify as candidate
biomarkers of smouldering vessel inflammation. Our find-
ings are in line with the notion that GCs do not sufficiently
suppress vascular inflammation [13]. Calprotectin (MRP8/
14 or S100A8/9) is a calcium binding protein that acts as a
damage-associated molecular pattern signal on the TLR4
and RAGE receptors [34]. It is released by monocytes and
neutrophils after interaction with endothelial cells during
migration [35]. Importantly, calprotectin levels did not cor-
relate with IL-6 and the acute-phase response.
Calprotectin levels remained high in treated patients, sug-
gesting ongoing monocyte/neutrophil tissue migration and
innate immune activation. Surprisingly, calprotectin levels
remained elevated in treatment-free remission. YKL-40 is
a marker expressed by mature macrophages, thought to
be involved in tissue remodelling and angiogenesis [36,
37]. It is expressed by non-classical monocytes in the
blood and by macrophages and giant cells in GCA TABs
[24, 38]. In vitro, YKL-40 production by macrophages is
sensitive to GCs [39]. In our study, however, long-term
high-dose GC treatment did not lead to a direct decrease
in serum YKL-40 levels, suggesting that YKL-40-produ-
cing cells are GC resistant. High YKL-40 levels at baseline
predicted a long time to GC-free remission. Our observa-
tion of strong YKL-40 expression in TABs in the intima-
media border region suggests that this protein is mainly
released in fully developed GCA with transmural inflam-
mation, which may be more GC resistant. Interestingly,
YKL-40 levels were clearly decreased in treatment-free
remission, which may point towards resolution of
inflammation.
We found a strong correlation between IL-6, CRP/ESR
and SAA at baseline in GCA patients. This was not the
case in infection controls, where levels of SAA were not
correlated with IL-6, implying that other cytokines stimu-
late hepatocytes to produce SAA, such as IL-1b or TNFa,
cytokines that are reportedly not increased in GCA [20,
40]. We found SAA also expressed at the tissue level.
SAA may amplify the local inflammatory response, as
O’Neill et al. [21] showed that stimulation with SAA
induced the production of IL-6, VEGF and angiopoietin-2
in TAB explants.
We observed a stronger acute-phase response in pa-
tients with overlapping C-GCA and LV-GCA compared
with patients with C-GCA or LV-GCA alone. Recent re-
views addressed the similarities and differences between
C-GCA and LV-GCA patients [2, 3, 14]. It is currently still
debated which patient group expresses the strongest
acute-phase response: C-GCA, LV-GCA or patients with
overlapping symptoms [3, 41]. High levels of acute-phase
proteins in patients with overlapping symptoms may be
due to a higher inflammatory load (more inflamed vessels)
and consequently greater net IL-6 production and ensuing
acute-phase response.
Patients with ischaemic ocular involvement presented
with a weaker acute-phase response, in line with previous
reports [4244]. In contrast, we did not observe a weak
acute-phase response in patients presenting with other
ischaemic symptoms, such as claudication. It has been
suggested that high levels of IL-6 are protective against
ischaemic events by promoting neoangiogenesis [44].
Thus it could be expected that IL-6, via a similar mechan-
ism, is protective against claudication as well, which was
not the case in our cohort. Therefore it is more likely that
patients with visual symptoms present earlier in the dis-
ease course not yet having developed more extensive
vessel wall inflammation.
This study has several strengths. The selection of bio-
markers was based on a strong rationale—their potential
involvement in GCA immunopathogenesis. Also, we
included newly diagnosed GCA patients before the start
of GC treatment. This is an important strength, as we
observed a strong effect of GCs on most serum markers.
Furthermore, newly diagnosed, treatment-naive patients
were prospectively followed for up to 7 years and samples
were taken at fixed time points. Patients were intensively
monitored by frequent follow-up visits according to proto-
col and extra visits in between in case of suspicion of a
relapse. This allowed us to calculate the exact time to
8 https://academic.oup.com/rheumatology
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GC-free remission. Due to the already long-standing
follow-up, we were also able to include treatment-free re-
mission samples. This revealed that many serum markers
are still elevated for an extended period of time. Another
advantage of our study design is the inclusion of two con-
trol populations: age- and sex-matched HCs and age-
matched INFs, allowing us to discriminate between dis-
ease-specific and non-specific events.
Our study has the following limitations: low numbers of
patients with active disease during treatment and low
numbers of patients in treatment-free remission (both
n< 10). The latter limitation is obviously due to the
length of the disease course. This implies that the data
in active disease and in treatment-free remission should
be taken with caution. Data from this study cannot yet be
extended to GCA patients treated with tocilizumab.
The serum markers in this study may aid in designing
personalized medicine for easy- (short-term GC requiring)
and difficult-to-treat (long-term GC requiring) GCA patients.
Patients at baseline may be stratified based on VEGF,
angiopoietins and possibly YKL-40 levels for a quick or a
slow GC tapering scheme. It is yet unclear whether these
markers have a similar predictive value in patients on IL-6R
blockade treatment. The predictive values of angiogenesis-
related serum markers require further confirmation. Future
studies on tissue inflammation markers may focus on cal-
protectin or YKL-40, especially to prevent aneurysms and
aortic dissection. PET-CT or follow-up biopsies would
allow us to determine whether these markers correlate
with silently ongoing tissue inflammation. If calprotectin
and/or YKL-40 are confirmed as markers of tissue inflam-
mation, monitoring their levels would be implied to prevent
recurrence of disease in GCA patients in remission.
To conclude, this prospective study identified a profile of
angiogenic and macrophage serum markers that predict
disease course in GCA. This profile outperformed the clas-
sic GCA biomarkers CRP and ESR. In addition, calprotectin
and/or YKL-40 may prove useful as IL-6-independent bio-
markers monitoring vessel inflammation during treatment.
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